Singapore markets closed
Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,501.18 +1,078.52 (+1.70%) CMC Crypto 200
1,385.90 +73.27 (+5.81%)
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 14.31B |
| Enterprise value | 31.23B |
| Trailing P/E | 872.00 |
| Forward P/E | 5.37 |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 0.90 |
| Price/book (mrq) | 1.93 |
| Enterprise value/revenue | 1.97 |
| Enterprise value/EBITDA | 20.05 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.06 |
| 52-week change 3 | 53.05% |
| S&P500 52-week change 3 | 21.23% |
| 52-week high 3 | 14.47 |
| 52-week low 3 | 7.09 |
| 50-day moving average 3 | 13.42 |
| 200-day moving average 3 | 10.64 |
Share statistics
| Avg vol (3-month) 3 | 10.49M |
| Avg vol (10-day) 3 | 9.43M |
| Shares outstanding 5 | 1.13B |
| Implied shares outstanding 6 | 1.13B |
| Float 8 | 1.11B |
| % held by insiders 1 | 0.00% |
| % held by institutions 1 | 52.60% |
| Shares short (28 Mar 2024) 4 | 11.56M |
| Short ratio (28 Mar 2024) 4 | 1.34 |
| Short % of float (28 Mar 2024) 4 | N/A |
| Short % of shares outstanding (28 Mar 2024) 4 | 1.03% |
| Shares short (prior month 29 Feb 2024) 4 | 14.72M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | 2.95 |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 12 Dec 2017 |
| Ex-dividend date 4 | 27 Nov 2017 |
| Last split factor 2 | 2:1 |
| Last split date 3 | 01 Jul 2004 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | -3.53% |
| Operating margin (ttm) | 28.05% |
Management effectiveness
| Return on assets (ttm) | 4.54% |
| Return on equity (ttm) | -7.36% |
Income statement
| Revenue (ttm) | 15.85B |
| Revenue per share (ttm) | 14.16 |
| Quarterly revenue growth (yoy) | 14.80% |
| Gross profit (ttm) | N/A |
| EBITDA | 4.33B |
| Net income avi to common (ttm) | -559M |
| Diluted EPS (ttm) | -0.50 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 3.23B |
| Total cash per share (mrq) | 2.88 |
| Total debt (mrq) | 20.27B |
| Total debt/equity (mrq) | 249.48% |
| Current ratio (mrq) | 1.02 |
| Book value per share (mrq) | 6.70 |
Cash flow statement
| Operating cash flow (ttm) | 1.37B |
| Levered free cash flow (ttm) | 3.29B |
© 2024 Yahoo. All rights reserved.